SCHEMBL4153972

SCHEMBL4153972

CC(C)(C)OC(=O)N1CC(Cc2ccccc2C(F)(F)F)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.50
RORC P51449 1/20 0.46
TACR1 P25103 2/20 0.43
NR1H2 P55055 1/20 0.43
EPHX2 P34913 1/20 0.42
KDM4E B2RXH2 2/20 0.42
PKM P14618 1/20 0.42
USP30 Q70CQ3 1/20 0.42
ALDH1A1 P00352 1/20 0.41
P2RX7 Q99572 2/20 0.41
GPR119 Q8TDV5 2/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
ACKR3 P25106 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1815968 0.88 KDM4E (0.54) EPHX2KDM4EPKMALDH1A1GPR119
SCHEMBL23830741 0.83 NAMPT (0.53) NAMPTRORCNR1H2EPHX2KDM4E
SCHEMBL3957772 0.83 CARM1 (0.47) NAMPTRORCTACR1EPHX2KDM4E
SCHEMBL28983817 0.82 NAMPT (0.52) NAMPTRORCNR1H2KDM4EPKM
SCHEMBL4166538 0.81 KDM4E (0.46) KDM4EALDH1A1
SCHEMBL2278226 0.81 NAMPT (0.51) NAMPTRORCNR1H2KDM4EPKM
SCHEMBL18301520 0.81 KDM4E (0.38) RORCTACR1NR1H2KDM4EALDH1A1
SCHEMBL1374782 0.81 KDM4E (0.38) RORCTACR1NR1H2KDM4EALDH1A1
SCHEMBL18404557 0.81 KDM4E (0.51) NAMPTKDM4EPKMUSP30GPR119
SCHEMBL26612279 0.81 RBP4 (0.53) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170828-A1 Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase MERCK FROSST CANADA LTD. (CA) 2009-07-02 US disclosed
US-20090170828-A1 Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase MERCK FROSST CANADA LTD. (CA) 2009-07-02 US disclosed
US-20090170828-A1 Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase MERCK FROSST CANADA LTD. (CA) 2009-07-02 US disclosed
WO-2007143823-A1 AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170828-A1 Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase SCD, SCD5, FASN NAMPT 1109/4885RORC 2058/4885TACR1 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.